Efficacy/Safety of Telmisartan/Amlodipine/Rosuvastatin in Hypertensive Patients With Hyperlipidemia

Inclusion criteria

• 19 years old or above
• Patients who confirmed essential hypertension with Hyperlipidemia or use of drugs at Visit 1 (sit systolic blood pressure ≥ 140mmHg, LDL-Cholesterol ≥ 100mg/dL)
• Patients who can stop the treatment of anti-hypertensive/anti-hyperlipidemic drugs in the opinion of the investigator
• Test results showing the following values at screening time (Visit 2) : sit systolic blood pressure >140mmHg
• Test results showing the following values at screening time (Visit 2) : 100< LDL-Cholesterol <250
• Patients who agreed to participate in the trial

Exclusion criteria

• Severe hypertension patients(systolic blood pressure ≥ 180 mm Hg or diastolic blood pressure ≥ 110 mm Hg)

-The change of mean sit systolic blood pressure ≥ 20 mmHg or sit diastolic blood pressure ≥ 10 mmHg on target arm between 1st and 2nd measurement

• LDL-Cholesterol > 250 mg/dL or triacylglycerol ≥ 400 mg/dL at screening time(Visit 1)
• Patients with postural hypotension who have sign and symptom
• Patients with secondary blood pressure(for example,aortic coarctation, hyperaldosteronism, renal artery stenosis, Cushing's syndrome, pheochromocytoma, Polycystic Kidney Diseases)
• Patients with congestive heart failure(New York Heart Association class III~IV)
• Patients with history of acute coronary syndrome or underwent revascularization (percutaneous transluminal coronary angioplasty or Coronary Artery Bypass Graft surgery ) within 6 months
• Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter or clinically significant arrhythmia
• Causes of hemodynamic disorder or structural heart defect such as valvular heart disease
• Patients who have history of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months prior to study entry
• Patients with primary aldosteronism
• Patients with severe ocular disorders
• Patients with autoimmune disease
• Patients with any chronic inflammation disease needed to chronic inflammation therapy
• Patients with uncontrolled diabetes Mellitus with HbA1c > 9% or thyroid diseases(TSH ≥ 1.5 X ULN)
• Patients who have a history of myopathy or rhabdomyolysis
• Patients who have 3 times of upper limit of normal range of muscle enzyme (creatinine kinase, CK)
• History of malignant tumor including leukemia, lymphoma within 5 years
• Patients with one kidney
• Patients with biliary obstructive disorder
• Patients with clinically significant electrolyte disturbance
• Continued serum potassium concentration abnormal status (<3.5mEq/L or >5.5mEq/L)
• Patients with sodium ion or body fluid is depleted and not able to correct
• Patients with clinically significant liver/renal disease
• Patients with digestive diseases that may affect the absorption or history in gastrointestinal surgery
• Patients who are dependent on drugs or alcohol
• Pregnancy, breast-feeding, or child-bearing potential Patients
• Patients with hypersensitivity to telmisartan or other angiotensin II receptor blockers
• Patients with hypersensitivity to Amlodipine or other dihydropyridine drugs
• Patients with history of Myotoxicity to other 3-hydroxy-methyl glutaryl-coenzyme A reductase inhibitor or fibrate
• Patients who are unable to stop taking prohibited drugs to combination during study period
• Patients who have galactose intolerance
• Patients taking other clinical trial drugs within 30 days from the time of visit for screening
• Patients that is not eligible to participate at the discretion of study investigator